ACCURAY INC
For the period ended Jun 30, 2026. Filed Aug 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Aug 27, 2026
ARAY$3.19-16.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share amounts)
| Years Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Net revenue: | ||
| Products (a) | $172,712 | $237,580 |
| Services (b) | 229,235 | 220,925 |
| Total net revenue | 401,947 | 458,505 |
| Cost of revenue: | ||
| Cost of products | 132,297 | 162,569 |
| Cost of services | 158,196 | 148,969 |
| Total cost of revenue (c) | 290,493 | 311,538 |
| Gross profit | 111,454 | 146,967 |
| Operating expenses: | ||
| Research and development (d) | 37,753 | 47,942 |
| Selling and marketing | 38,573 | 43,315 |
| General and administrative | 45,398 | 47,871 |
| Restructuring | 16,172 | — |
| Total operating expenses | 137,896 | 139,128 |
| Income (loss) from operations | (26,442) | 7,839 |
| Income from equity method investment | 1,124 | 4,714 |
| Interest expense | (32,905) | (12,954) |
| Gain on extinguishment of debt | — | 1,475 |
| IEEPA refund financing costs | (2,405) | — |
| Gain (loss) from change in fair value of warrant liability | 8,369 | (499) |
| Other income, net | 5,011 | 559 |
| Income (loss) before provision for income taxes | (47,248) | 1,134 |
| Provision for income taxes | 1,946 | 2,725 |
| Net loss | $(49,194) | $(1,591) |
| Net loss per share - basic and diluted | $(0.40) | $(0.02) |
| Weighted average common shares used in computing net loss per share: | ||
| Basic and diluted | 122,635 | 102,768 |
| Other Comprehensive Loss: | ||
| Net loss | $(49,194) | $(1,591) |
| Unrealized gain from cash flow hedges, net of reclassifications | $1,603 | $— |
| Foreign currency translation adjustment | (3,237) | 1,557 |
| Change in defined benefit pension obligation | (42) | 828 |
| Comprehensive income (loss) | $(50,870) | $794 |
| (a) | Includes sales of products to the joint venture, an equity method investment, of $42,965 during the year ended June 30, 2026, and $101,563 during the year ended June 30, 2025. See Note 11. |
|---|
| (b) | Includes sales of services to the joint venture, an equity method investment, of $22,604 during the year ended June 30, 2026, and $18,521 during the year ended June 30, 2025. See Note 11. |
|---|
| (c) | Includes cost of revenue from sales to the joint venture, an equity method investment, of $40,997 during the year ended June 30, 2026, and $74,421 during the year ended June 30, 2025. See Note 11. |
|---|
| (d) | Includes charge backs to the joint venture, an equity method investment, related to research and development of $1,294 during the year ended June 30, 2026, and $1,482 during the year ended June 30, 2025. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.